Analysts Boost Rhythm Pharmaceuticals Price Targets Amid Strong Momentum Analyst sentiment for Rhythm Pharmaceuticals has surged, with major firms raising price targets—HC Wainwright to $80, Canaccord to $92, and BofA to $63—following a remarkable 28% stock gain over three sessions. Year-to-date, the stock has reversed early losses, now up 0.27%, reflecting growing confidence in its pipeline and commercial strategy.12